Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD123 CAR-T in Acute Leukemia
NCT03672851Phase 1Terminated
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD123 CAR-T cells in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Dose-limiting toxicity at 28 days, Incidence of adverse events and 1 more. Started Apr 2019; status: terminated.
02
Drugs
anti-CD123 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03672851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672851.